BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 15507883)

  • 1. Omalizumab: efficacy in allergic disease.
    Spector S
    Panminerva Med; 2004 Jun; 46(2):141-8. PubMed ID: 15507883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease.
    Berger WE
    Ann Allergy Asthma Immunol; 2002 Feb; 88(2):152-60; quiz 161-2, 208. PubMed ID: 11868919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of allergic bronchial asthma with omalizumab - an anti-IgE monoclonal antibody.
    D'Amato G
    Expert Opin Biol Ther; 2003 Apr; 3(2):371-6. PubMed ID: 12662149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
    Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
    J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW; Massanari M; Kianifard F; Geba GP
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
    D'Amato G; Perticone M; Bucchioni E; Salzillo A; D'Amato M; Liccardi G
    Eur Ann Allergy Clin Immunol; 2010 Aug; 42(4):135-40. PubMed ID: 21114196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.
    Humbert M; Berger W; Rapatz G; Turk F
    Allergy; 2008 May; 63(5):592-6. PubMed ID: 18355388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
    Dodig S; Richter D; Cepelak I; Benko B
    Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.
    Owen CE
    Pharmacol Ther; 2007 Jan; 113(1):121-33. PubMed ID: 17000005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab: a novel therapy for allergic asthma.
    Davis LA
    Ann Pharmacother; 2004; 38(7-8):1236-42. PubMed ID: 15187202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.